XML 38 R32.htm IDEA: XBRL DOCUMENT v3.26.1
Revenue - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
May 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]            
Revenue $ 422,000 $ 142,000        
Upfront cash payment received 55,218,000   $ 52,096,000 $ 55,622,000    
Collaboration Agreement with AstraZeneca            
Disaggregation of Revenue [Line Items]            
Revenue 400,000 100,000        
Upfront cash payment received         $ 40,000,000 $ 20,000,000
Milestone payments received $ 0 $ 0 $ 10,000,000